37 completed. 37 Phase 2, 10 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 37 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 2 | Completed 2 |
Follow Bird Diseases: new trials by email Literature Review of Bird Diseases trials Research Report on Bird Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3. - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 991 | 2024-04-18 | 2026-02-05 |
| A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22 - Influenza, Human, Influenza in Birds | Phase 2 | Completed | Seqirus | 260 | 2022-07-18 | 2026-05-13 |
| 2017 A/H7N9 IIV Revaccination A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 304 | 2018-12-18 | 2021-07-30 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 372 | 2018-11-02 | 2021-05-17 |
| 2013/2017 H7N9 Prime-Boost Interval A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2018-08-21 | 2021-08-02 |
| Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 VN, IN, dk/BANG - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 720 | 2018-03-15 | 2020-07-14 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine - Avian Influenza, Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 149 | 2018-02-20 | 2020-08-06 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 720 | 2018-02-14 | 2024-09-19 |
| Panblok H7 Vaccine Adjuvanted With AS03 or MF59 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7 - Influenza, Human | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 366 | 2017-09-20 | 2020-05-06 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 IVACFLU-A/H5N1 vaccine, Placebo - Avian Influenza | Phase 2 / Phase 3 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 930 | 2017-03-07 | 2019-05-21 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine - Avian Influenza, H1N1 Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2016-11-07 | 2024-10-09 |
| H7N9 Boost in Healthy Adults Monovalent influenza A/H7N9 virus vaccine - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2016-01-12 | 2018-08-22 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 479 | 2014-10-01 | 2017-07-06 |
| Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine OrniFlu® inactivated vaccine - Avian Influenza | Phase 2 | Completed | Mahidol University | 60 | 2014-06-01 | 2015-04-09 |
| Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2013-07-01 | 2019-02-12 |
| Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects Adjuvanted H5N1 pandemic influenza vaccine - Pandemic H5N1 Influenza | Phase 2 | Completed | Novartis Vaccines | 1393 | 2013-01-01 | 2019-01-30 |
| Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults Adjuvanted H5N1 pandemic influenza vaccine - Pandemic H5N1 Influenza | Phase 2 | Completed | Novartis Vaccines | 979 | 2013-01-01 | 2015-02-03 |
| Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children Adjuvanted H5N1 pandemic influenza vaccine - Pandemic H5N1 Influenza | Phase 2 | Completed | Novartis Vaccines | 662 | 2013-01-01 | 2019-01-16 |
| H5N1 Vaccine Study in Japanese Adults H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated) - H5N1 Influenza | Phase 2 / Phase 3 | Completed | Alachua Government Services, Inc. | 340 | 2011-06-01 | 2015-10-09 |
| Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults Recombinant Influenza HA Vaccine (H5N1) - Influenza | Phase 2 | Completed | UMN Pharma Inc. | 87 | 2010-10-01 | 2011-02-08 |
Showing 20 of 37. Sign in to see all of them.
Influenza in Birds (37) · Influenza, Human (30) · Orthomyxoviridae Infections (3) · Virus Diseases (3) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Dyspnea (1) · Infections (1)
Animal Diseases (37) · Infections (36) · RNA Virus Infections (35) · Orthomyxoviridae Infections (34) · Virus Diseases (34) · Respiratory Tract Diseases (28) · Respiratory Tract Infections (28) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1) · Signs and Symptoms (1) · Signs and Symptoms, Respiratory (1)
Influenza Vaccines (5) · MF59 oil emulsion (3) · AS03 adjuvant (2) · Aluminum Hydroxide (2) · Adjuvants, Pharmaceutic (1) · FluBlok (1) · Oseltamivir (1) · SE 1-step Futurabond M (1) · Vaccines (1) · chiron (1)
National Institute of Allergy and Infectious Diseases (NIAID) (18) · Novartis Vaccines (7) · Alachua Government Services, Inc. (3) · Biomedical Advanced Research and Development Authority (2) · GlaxoSmithKline (1) · Green Cross Corporation (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1) · Mahidol University (1) · Novartis (1) · Seqirus (1) · UMN Pharma Inc. (1)
United States (24) · Thailand (5) · Australia (3) · Finland (3) · Japan (2) · Singapore (2) · Vietnam (2) · Austria (1) · Colombia (1) · Germany (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Alexander Geisberger, MD (1) · Carlos Fierro, MD (1) · Gerald Aichinger, MD (1) · Mark Adams, MD (1) · Matthew Davis, MD (1) · Nadine Rouphael, MD (1) · Punnee Pitisuttithum (1) · Tawee Chotpitayasunohdh, MD (1) · Terry Poling, MD (1)
PMID 39756216, PMID 30968056, PMID 18237269, PMID 18260764, PMID 18808338, PMID 19416838, PMID 20810680, PMID 20819892, PMID 21282194, PMID 21606530, PMID 22777094, PMID 23536690, PMID 23723457, PMID 24041789, PMID 24047817, PMID 28533093, PMID 30955980, PMID 31194712, PMID 31812464, PMID 34174187, PMID 34711436, PMID 35465983, PMID 37466221, PMID 38537255, PMID 39798434, PMID 42630599
U19AI090023 (1)